Skip to main content

Table 2 PD-L1 expression in cholangiocarcinoma subtypes (tumor and stromal cells; PD-L1 antibody clone: SP263)

From: Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies

Tumor subgroups Tumor Stroma
Positive Negative Positive Negative
iCCA, n = 72
 n (%) 8 (11) 64 (89) 22 (31) 50 (69)
 % cells, median (range) 15 (5–30) n.a. 5 (1–40) n.a.
pCCA, n = 57
 n (%) 6 (11) 51 (89) 23 (40) 34 (60)
 % cells, median (range) 10 (5–80) n.a. 5 (2–30) n.a.
dCCA, n = 41
 n (%) 5 (12) 36 (88) 25 (61) 16 (39)
 % cells, median (range) 10 (5–30) n.a. 5 (1–30) n.a.
  1. iCCA intrahepatic cholangiocarcinoma, pCCA perihilar cholangiocarcinoma, dCCA distal cholangiocarcinoma, n.a. not applicable
\